(Q34122643)

31 July 2017

1 reference

title

Agomelatine, the first melatonergic antidepressant: discovery, characterization and development (English)

1 reference

31 July 2017

Christian de Bodinat

1

1 reference

31 July 2017

Béatrice Guardiola-Lemaitre

2

1 reference

31 July 2017

Elisabeth Mocaër

3

1 reference

31 July 2017

Pierre Renard

4

1 reference

31 July 2017

Carmen Muñoz

5

1 reference

31 July 2017

Mark J Millan

6

1 reference

31 July 2017

publication date

25 June 2010

1 reference

Nature Reviews Drug Discovery

31 July 2017

published in

1 reference

31 July 2017

volume

9

1 reference

31 July 2017

issue

8

1 reference

31 July 2017

page(s)

628-642

1 reference

Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence.

31 July 2017

cites work

1 reference

Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application

31 March 2020

1 reference

Efficacy of Bupropion and the Selective Serotonin Reuptake Inhibitors in the Treatment of Major Depressive Disorder With High Levels of Anxiety (Anxious Depression)

31 March 2020

1 reference

Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms

31 March 2020

1 reference

Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs

31 March 2020

1 reference

Novel drugs and therapeutic targets for severe mood disorders

31 March 2020

1 reference

Improving antidepressant drugs: update on recently patented compounds

31 March 2020

1 reference

Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents

31 March 2020

1 reference

Which antidepressants have demonstrated superior efficacy? A review of the evidence

31 March 2020

1 reference

Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders

31 March 2020

1 reference

The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders

31 March 2020

1 reference

Tachykinin receptors as therapeutic targets in stress-related disorders.

31 March 2020

1 reference

Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression

31 March 2020

1 reference

A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression

31 March 2020

1 reference

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

31 March 2020

1 reference

Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression

31 March 2020

1 reference

Stress, depression, and neuroplasticity: a convergence of mechanisms

31 March 2020

1 reference

Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality.

31 March 2020

1 reference

Circadian rhythms and the pharmacology of affective illness

31 March 2020

1 reference

Circadian rhythm disturbances in depression

31 March 2020

1 reference

Comparative aspects of the pineal/melatonin system of poikilothermic vertebrates.

31 March 2020

1 reference

Melatonin: Nature's most versatile biological signal?

31 March 2020

1 reference

Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology

31 March 2020

1 reference

Specific Binding of Melatonin in Bovine Brain*

31 March 2020

1 reference

Hypothalamic melatonin receptor sites revealed by autoradiography

31 March 2020

1 reference

Melatonin receptors step into the light: cloning and classification of subtypes

31 March 2020

1 reference

Melatonin receptors: localization, molecular pharmacology and physiological significance

31 March 2020

1 reference

Human pineal physiology and functional significance of melatonin

31 March 2020

1 reference

The interaction between the internal clock and antidepressant efficacy.

31 March 2020

1 reference

Novel naphthalenic ligands with high affinity for the melatonin receptor

31 March 2020

1 reference

Comparative effects of a melatonin agonist on the circadian system in mice and Syrian hamsters

31 March 2020

1 reference

Melatonin analogues as agonists and antagonists in the circadian system and other brain areas.

31 March 2020

1 reference

New selective ligands of human cloned melatonin MT1 and MT2 receptors.

31 March 2020

1 reference

Melatonin receptors and their regulation: biochemical and structural mechanisms

31 March 2020

1 reference

Short-term exposure to melatonin differentially affects the functional sensitivity and trafficking of the hMT1 and hMT2 melatonin receptors

31 March 2020

1 reference

Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin

31 March 2020

1 reference

Chronic exposure to melatonin receptor agonists does not alter their effects on suprachiasmatic nucleus neurons

31 March 2020

1 reference

Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent

31 March 2020

1 reference

Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms

31 March 2020

1 reference

Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS).

31 March 2020

1 reference

Chronotherapeutics (light and wake therapy) in affective disorders

31 March 2020

1 reference

Circadian misalignment in major depressive disorder

31 March 2020

1 reference

Effects of a novel melatonin analog on circadian rhythms of body temperature and activity in young, middle-aged, and old rats

31 March 2020

1 reference

Melatonin and its new agonist S-20098 restore synchronized sleep fragmented by experimental trypanosome infection in the rat.

31 March 2020

1 reference

Resynchronisation of a diurnal rodent circadian clock accelerated by a melatonin agonist

31 March 2020

1 reference

Modulation of voltage-dependent Ca2+ conductance by changing Cl- concentration in rat lactotrophs

31 March 2020

1 reference

Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal

31 March 2020

1 reference

Organization of rat circadian rhythms during daily infusion of melatonin or S20098, a melatonin agonist

31 March 2020

1 reference

Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?

31 March 2020

1 reference

Melatonin and S-20098 increase REM sleep and wake-up propensity without modifying NREM sleep homeostasis

31 March 2020

1 reference

Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature

31 March 2020

1 reference

Regulation of serotonin-2C receptor G-protein coupling by RNA editing

31 March 2020

1 reference

Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions

31 March 2020

1 reference

Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors

31 March 2020

1 reference

Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction

31 March 2020

1 reference

Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus

31 March 2020

1 reference

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

31 March 2020

1 reference

Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems

31 March 2020

1 reference

Serotonin 5-HT2c agonists mimic the effect of light pulses on circadian rhythms

31 March 2020

1 reference

Circadian tryptophan hydroxylase levels and serotonin release in the suprachiasmatic nucleus of the rat.

31 March 2020

1 reference

Activation of 5-HT2C receptors acutely induces Per1 gene expression in the rat SCN in vitro

31 March 2020

1 reference

New light on the serotonergic paradox in the rat circadian system.

31 March 2020

1 reference

Serotonin1A autoreceptor activation by S 15535 enhances circadian activity rhythms in hamsters: evaluation of potential interactions with serotonin2A and serotonin2C receptors

31 March 2020

1 reference

SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants

31 March 2020

1 reference

Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action

31 March 2020

1 reference

Effect of agomelatine in the chronic mild stress model of depression in the rat.

31 March 2020

1 reference

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

31 March 2020

1 reference

Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis

31 March 2020

1 reference

Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus.

31 March 2020

1 reference

Antidepressant action of agomelatine (S 20098) in a transgenic mouse model

31 March 2020

1 reference

Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function

31 March 2020

1 reference

S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models

31 March 2020

1 reference

Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model.

31 March 2020

1 reference

Effects of melatonin receptor ligands on swim test immobility

31 March 2020

1 reference

Melatonin receptor (MT1) knockout mice display depression-like behaviors and deficits in sensorimotor gating.

31 March 2020

1 reference

Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture

31 March 2020

1 reference

Antidepressants and sleep: a qualitative review of the literature

31 March 2020

1 reference

Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.

31 March 2020

1 reference

Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness

31 March 2020

1 reference

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

31 March 2020

1 reference

Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression

31 March 2020

1 reference

Antidepressants and the placebo response

31 March 2020

1 reference

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

31 March 2020

1 reference

Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine

31 March 2020

1 reference

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline

31 March 2020

1 reference

A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.

31 March 2020

1 reference

Pathophysiology of depression: role of sleep and the melatonergic system

31 March 2020

1 reference

Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

31 March 2020

1 reference

Discontinuation symptoms in depression and anxiety disorders

31 March 2020

1 reference

Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis

31 March 2020

1 reference

Acute low doses of melatonin restore full sexual activity in impotent male rats

31 March 2020

1 reference

Melatonin protects against the effects of chronic stress on sexual behaviour in male rats

31 March 2020

1 reference

Dopamine and serotonin: influences on male sexual behavior

31 March 2020

1 reference

Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale.

31 March 2020

1 reference

Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants

31 March 2020

1 reference

Sleep, memory, and plasticity

31 March 2020

1 reference

Adult hippocampal neurogenesis, synaptic plasticity and memory: facts and hypotheses

31 March 2020

1 reference

Circadian rhythms and memory: not so simple as cogs and gears

31 March 2020

1 reference

Cognitive deficits in depression: possible implications for functional neuropathology

31 March 2020

1 reference

The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats

31 March 2020

1 reference

Prevalence of depressive symptoms and syndromes in later life in ten European countries: the SHARE study.

31 March 2020

1 reference

The diagnosis, symptomatology, and epidemiology of seasonal affective disorder.

31 March 2020

1 reference

Agomelatine in the treatment of seasonal affective disorder

31 March 2020

1 reference

Managing the patient with co-morbid depression and an anxiety disorder

31 March 2020

1 reference

Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCN.

31 March 2020

1 reference

Serotonin 5-HT(2C) receptors regulate anxiety-like behavior

31 March 2020

1 reference

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade

31 March 2020

1 reference

Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study

31 March 2020

1 reference

Melatonin in mood disorders

31 March 2020

1 reference

Circuit projection from suprachiasmatic nucleus to ventral tegmental area: a novel circadian output pathway

31 March 2020

1 reference

Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus

31 March 2020

1 reference

12 December 2020

Nonpharmacological, somatic treatments of depression: electroconvulsive therapy and novel brain stimulation modalities

1 reference

12 December 2020

SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants

1 reference

12 December 2020

Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors.

1 reference

12 December 2020

Multi- and single-target agents for major psychiatric diseases: therapeutic opportunities and challenges.

1 reference

12 December 2020

Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies

1 reference

12 December 2020

Tolerability of modern antidepressants

1 reference

12 December 2020

Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder

1 reference

12 December 2020

New naphthalenic ligands of melatoninergic receptors

1 reference

12 December 2020

Major depressive disorder, sleep EEG and agomelatine: an open-label study

1 reference

12 December 2020

Influence of sleep-wake and circadian rhythm disturbances in psychiatric disorders

1 reference

12 December 2020

Weight gain in the treatment of mood disorders

1 reference

12 December 2020

Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD3140

1 reference

Dimensions Publication ID

31 July 2017

1038845929

0 references

1 reference